RU2746314C2 - Антитела анти-tnfrsf25 - Google Patents

Антитела анти-tnfrsf25 Download PDF

Info

Publication number
RU2746314C2
RU2746314C2 RU2018143977A RU2018143977A RU2746314C2 RU 2746314 C2 RU2746314 C2 RU 2746314C2 RU 2018143977 A RU2018143977 A RU 2018143977A RU 2018143977 A RU2018143977 A RU 2018143977A RU 2746314 C2 RU2746314 C2 RU 2746314C2
Authority
RU
Russia
Prior art keywords
leu
ala
antibody
gly
ser
Prior art date
Application number
RU2018143977A
Other languages
English (en)
Russian (ru)
Other versions
RU2018143977A3 (enExample
RU2018143977A (ru
Inventor
Тейлор Х. ШРЕЙБЕР
Джефф Т. ХАТЧИНС
Original Assignee
Пеликан Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пеликан Терапьютикс, Инк. filed Critical Пеликан Терапьютикс, Инк.
Publication of RU2018143977A publication Critical patent/RU2018143977A/ru
Publication of RU2018143977A3 publication Critical patent/RU2018143977A3/ru
Application granted granted Critical
Publication of RU2746314C2 publication Critical patent/RU2746314C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018143977A 2016-06-09 2017-06-09 Антитела анти-tnfrsf25 RU2746314C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348009P 2016-06-09 2016-06-09
US62/348,009 2016-06-09
PCT/US2017/036817 WO2017214547A1 (en) 2016-06-09 2017-06-09 Anti-tnfrsf25 antibodies

Publications (3)

Publication Number Publication Date
RU2018143977A RU2018143977A (ru) 2020-07-09
RU2018143977A3 RU2018143977A3 (enExample) 2020-10-05
RU2746314C2 true RU2746314C2 (ru) 2021-04-12

Family

ID=59078259

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018143977A RU2746314C2 (ru) 2016-06-09 2017-06-09 Антитела анти-tnfrsf25

Country Status (15)

Country Link
US (3) US10005843B2 (enExample)
EP (1) EP3468998B1 (enExample)
JP (1) JP6961625B2 (enExample)
KR (1) KR102423942B1 (enExample)
CN (1) CN109219620B (enExample)
AU (1) AU2017278192A1 (enExample)
BR (1) BR112018075222A2 (enExample)
CA (1) CA3026652A1 (enExample)
DK (1) DK3468998T3 (enExample)
IL (1) IL263406B2 (enExample)
MX (1) MX389320B (enExample)
RU (1) RU2746314C2 (enExample)
SG (1) SG11201810853UA (enExample)
WO (1) WO2017214547A1 (enExample)
ZA (1) ZA201808317B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014531210A (ja) 2011-09-30 2014-11-27 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ＴＬ１ａに対する抗体およびその使用
US10046047B2 (en) * 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US20220298252A1 (en) * 2019-08-30 2022-09-22 Pelican Therapeutics, Inc. Methods of treating cancer using tnfrsf25 antibodies
CA3151319A1 (en) * 2019-09-26 2021-04-01 Matthew M. Seavey Tnfrsf25-mediated treatments of immune diseases and disorders
WO2022212668A1 (en) * 2021-03-31 2022-10-06 Heat Biologics, Inc. Methods and compositions related to tnfrsf25/dr3 agonists
CN119256009A (zh) * 2022-06-17 2025-01-03 塞莱克辛有限公司 与人dr3特异性结合的抗体及其用途
CN120365425B (zh) * 2023-06-02 2025-12-16 安徽金百奥生物科技有限公司 一种靶向dr3胞外域的纳米抗体
GB202315963D0 (en) 2023-10-18 2023-11-29 Cancer Research Tech Ltd Binding molecules
WO2025158389A1 (en) * 2024-01-24 2025-07-31 Shattuck Labs, Inc. Antibodies that bind tnfrsf25

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011017303A1 (en) * 2009-08-03 2011-02-10 University Of Miami Method for in vivo expansion of t regulatory cells
RU2551235C2 (ru) * 2013-08-26 2015-05-20 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
WO2016081455A1 (en) * 2014-11-17 2016-05-26 Pelican Therapeutics, Inc. Human tnfrsf25 antibody

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1992015683A1 (en) 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
AU684041B2 (en) 1992-02-19 1997-12-04 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US20080233119A2 (en) 2003-08-20 2008-09-25 University Of Miami Compositions and methods for treating inflammatory lung disease
US7612179B2 (en) 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
EP1919954B1 (en) 2005-08-30 2016-10-19 University of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
AR063086A1 (es) 2006-10-02 2008-12-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y usos de los mismos
FR2907341B1 (fr) 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
KR20210041631A (ko) 2013-01-09 2021-04-15 유니버시티 오브 마이애미 TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
CN103592439B (zh) * 2013-09-03 2015-10-21 天津亿美诺生物科技有限公司 人尿路上皮癌特异性抗体及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011017303A1 (en) * 2009-08-03 2011-02-10 University Of Miami Method for in vivo expansion of t regulatory cells
RU2551235C2 (ru) * 2013-08-26 2015-05-20 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
WO2016081455A1 (en) * 2014-11-17 2016-05-26 Pelican Therapeutics, Inc. Human tnfrsf25 antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BYUNG-SU KIM et al., Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease, BLOOD, 2015, Vol.126, N.4, pp.546-557. *

Also Published As

Publication number Publication date
DK3468998T3 (en) 2022-03-07
US20210017287A1 (en) 2021-01-21
IL263406B2 (en) 2023-09-01
MX389320B (es) 2025-03-20
RU2018143977A3 (enExample) 2020-10-05
US10005843B2 (en) 2018-06-26
KR20190015716A (ko) 2019-02-14
WO2017214547A1 (en) 2017-12-14
EP3468998B1 (en) 2021-12-01
IL263406A (en) 2018-12-31
JP2019526528A (ja) 2019-09-19
AU2017278192A1 (en) 2018-12-13
JP6961625B2 (ja) 2021-11-10
US10683359B2 (en) 2020-06-16
RU2018143977A (ru) 2020-07-09
ZA201808317B (en) 2019-08-28
KR102423942B1 (ko) 2022-07-22
MX2018014716A (es) 2019-03-11
CA3026652A1 (en) 2017-12-14
US20170355773A1 (en) 2017-12-14
CN109219620A (zh) 2019-01-15
EP3468998A1 (en) 2019-04-17
BR112018075222A2 (pt) 2019-03-19
CN109219620B (zh) 2023-01-31
SG11201810853UA (en) 2019-01-30
IL263406B1 (en) 2023-05-01
US20180312599A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
RU2746314C2 (ru) Антитела анти-tnfrsf25
KR102633423B1 (ko) 항-bcma 중쇄-단독 항체
KR102742528B1 (ko) 항-bcma 중쇄-단독 항체
EP2935332B1 (en) Anti-h7cr antibodies
US10683358B2 (en) Human TNFRSF25 antibody
CN109485729A (zh) Bcma和cd3的结合分子
JP2020524000A (ja) 抗ｂｃｍａ重鎖のみ抗体
KR102608028B1 (ko) 인간 원형질막 소포 관련 단백질 pv-1에 특이적으로 결합하는 단일클론항체 및 이의 제조방법과 용도
JP2024514246A (ja) Ｃｌｄｎ１８．２抗原結合タンパク質およびその使用
KR20230166120A (ko) 새로운 tnfr2 결합 분자
US20240270840A1 (en) Antibodies against cd112r and uses thereof
WO2022228545A1 (en) Antibodies and variants thereof against human 4-1bb
HK40007009B (en) Anti-tnfrsf25 antibodies
RU2781301C2 (ru) Анти-bcma антитела, содержащие только тяжёлую цепь
RU2816994C2 (ru) Антитела к bcma, содержащие только тяжелую цепь
TW202523698A (zh) 抗ｇｐｒｃ５ｄ抗體及組成物